Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

Similar articles for PubMed (Select 23824495)

1.

A case of delayed methotrexate clearance following administration of a complementary medication containing chlorophyll.

Brooks SL, Sanders J, Seymour JF, Mellor JD.

J Oncol Pharm Pract. 2014 Jun;20(3):225-8. doi: 10.1177/1078155213492553. Epub 2013 Jul 2.

PMID:
23824495
2.

Dosing algorithm to target a predefined AUC in patients with primary central nervous system lymphoma receiving high dose methotrexate.

Joerger M, Ferreri AJ, Krähenbühl S, Schellens JH, Cerny T, Zucca E, Huitema AD.

Br J Clin Pharmacol. 2012 Feb;73(2):240-7. doi: 10.1111/j.1365-2125.2011.04084.x.

3.

Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients.

Joerger M, Huitema AD, van den Bongard HJ, Baas P, Schornagel JH, Schellens JH, Beijnen JH.

Br J Clin Pharmacol. 2006 Jul;62(1):71-80.

4.

Toxic epidermal necrolysis following combination of methotrexate and trimethoprim-sulfamethoxazole.

Yang CH, Yang LJ, Jaing TH, Chan HL.

Int J Dermatol. 2000 Aug;39(8):621-3.

PMID:
10971734
6.

Early recognition of patients with decreased methotrexate clearance following high-dose methotrexate infusion therapy.

Ikeda H, Kihira K, Kuwata N, Arai S, Kimura Y, Miyake K, Kitaura T, Fujimura K, Kuramoto A, Fukuchi H.

Hiroshima J Med Sci. 1996 Jun;45(2):57-62.

PMID:
8810132
7.

Drug-drug interaction between methotrexate and levetiracetam resulting in delayed methotrexate elimination.

Bain E, Birhiray RE, Reeves DJ.

Ann Pharmacother. 2014 Feb;48(2):292-6. doi: 10.1177/1060028013511951. Epub 2013 Nov 18.

PMID:
24259648
8.

[Effect of Chai-ling-tang (Sairei-to) for methotrexate concentration degradation delay by methotrexate high-dose therapy].

Utsuki S, Oka H, Suzuki S, Sato S, Osawa S, Koizumi H, Miyajima Y, Fujii K.

No Shinkei Geka. 2010 Feb;38(2):133-7. Japanese.

PMID:
20166525
9.

Managing reduced methotrexate clearance in a patient with a heterozygous methylenetetrahydrofolate reductase gene polymorphism.

Gammon DC, Bhatt MS, Patel B, Anderson M, Van Horn A, Glantz MJ.

J Oncol Pharm Pract. 2008 Sep;14(3):153-6. doi: 10.1177/1078155208093931.

PMID:
18719070
10.

Pharmacokinetics of methotrexate in cerebrospinal fluid and serum after osmotic blood-brain barrier disruption in patients with brain lymphoma.

Zylber-Katz E, Gomori JM, Schwartz A, Lossos A, Bokstein F, Siegal T.

Clin Pharmacol Ther. 2000 Jun;67(6):631-41.

PMID:
10872645
11.

Delayed methotrexate clearance in osteosarcoma patients treated with multiagent regimens of neoadjuvant chemotherapy.

Bacci G, Ferrari S, Longhi A, Forni C, Loro L, Beghelli C, Tremosini M, Versari M.

Oncol Rep. 2003 Jul-Aug;10(4):851-7.

PMID:
12792734
12.

Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas.

Ferreri AJ, Guerra E, Regazzi M, Pasini F, Ambrosetti A, Pivnik A, Gubkin A, Calderoni A, Spina M, Brandes A, Ferrarese F, Rognone A, Govi S, Dell'Oro S, Locatelli M, Villa E, Reni M.

Br J Cancer. 2004 Jan 26;90(2):353-8.

13.

Urinary coproporphyrin I/(I + III) ratio as a surrogate for MRP2 or other transporter activities involved in methotrexate clearance.

Benz-de Bretagne I, Zahr N, Le Gouge A, Hulot JS, Houillier C, Hoang-Xuan K, Gyan E, Lissandre S, Choquet S, Le Guellec C.

Br J Clin Pharmacol. 2014 Aug;78(2):329-42. doi: 10.1111/bcp.12326.

14.
15.

Severe intoxication with methotrexate possibly associated with concomitant use of proton pump inhibitors.

Santucci R, Levêque D, Kemmel V, Lutz P, Gérout AC, N'guyen A, Lescoute A, Schneider F, Bergerat JP, Herbrecht R.

Anticancer Res. 2010 Mar;30(3):963-5.

PMID:
20393020
16.

Successful rescue with leucovorin and thymidine in a patient with high-dose methotrexate induced acute renal failure.

van den Bongard HJ, Mathĵt RA, Boogerd W, Schornagel JH, Soesan M, Schellens JH, Beijnen JH.

Cancer Chemother Pharmacol. 2001 Jun;47(6):537-40.

PMID:
11459208
17.

Prediction of methotrexate elimination after high dose infusion in children with acute lymphoblastic leukaemia using a population pharmacokinetic approach.

Odoul F, Le Guellec C, Lamagnère JP, Breilh D, Saux MC, Paintaud G, Autret-Leca E.

Fundam Clin Pharmacol. 1999;13(5):595-604.

PMID:
10520733
18.

Clinical relevance of consolidation radiotherapy and other main therapeutic issues in primary central nervous system lymphomas treated with upfront high-dose methotrexate.

Reni M, Ferreri AJ, Guha-Thakurta N, Blay JY, Dell'Oro S, Biron P, Hochberg FH.

Int J Radiat Oncol Biol Phys. 2001 Oct 1;51(2):419-25. Review.

PMID:
11567816
19.

High-dose methotrexate clearance following prior vancomycin administration: no significant interaction in the absence of overt renal impairment.

Shamash J, Joel S, Lundholm L, Millard L, Oliver T.

Ann Oncol. 2003 Jan;14(1):169-70. No abstract available.

20.

Treatment of methotrexate intoxication with various modalities of continuous extracorporeal therapy and glucarpidase.

Vilay AM, Mueller BA, Haines H, Alten JA, Askenazi DJ.

Pharmacotherapy. 2010 Jan;30(1):111. doi: 10.1592/phco.30.1.111.

PMID:
20030480
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk